A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009932/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and
effective therapy to improve glycemic control in patients with type 1 diabetes.
提供机构：
Vivli
创建时间：
2024-04-02
